Lilly’s Mirikizumab shows reduction of Intestinal Inflammation in Crohn’s Disease
Eli Lilly and Company revealed on Monday, new efficiency and safety results from the Phase 2 SERENITY trial assessing Mirikizumab
Read moreEli Lilly and Company revealed on Monday, new efficiency and safety results from the Phase 2 SERENITY trial assessing Mirikizumab
Read moreViiV Healthcare’s GEMINI studies showed that the 2-drug regimen (2DR) of dolutegravir plus lamivudine, appeared to have non-inferior potency in
Read moreUK clinicians are being advised to “think carefully” before ordering tests as pharma group Roche is experiencing logistical challenges due
Read moreBristol Myers Squibb is strengthening its cardiovascular pipeline through a $13.1 Billion acquisition of biotech firm MyoKardia. The $13.1 Billion
Read moreAstraZeneca’s FARXIGA® was granted Breakthrough Therapy Designation (BTD) in the U.S. for Chronic Kidney Disease, following the DAPA-CKD Phase III
Read moreAbbott declared the first patient has been enrolled in the DISTINCT study (Dorsal spInal cord STImulatioN vs mediCal management for
Read moreJanssen’s Golimumab, a human monoclonal antibody used as an immunosuppressive drug and sold under the brand name Simponi, has received
Read moreIrish biotechnology firm Inflazome announced today that it has closed a share purchase agreement with Swiss pharma giant Roche in
Read moreSwiss pharma giant Roche announced today new data that demonstrates OCREVUS® (ocrelizumab) is a highly effective treatment option for people
Read morePhase 3 clinical trials for the COVID-19 vaccine named AZD1222, developed by AstraZeneca and Oxford University, have been paused after
Read more